160 related articles for article (PubMed ID: 28727795)
1. Effect of therapy switch on time to second-line antiretroviral treatment failure in HIV-infected patients.
Häggblom A; Santacatterina M; Neogi U; Gisslen M; Hejdeman B; Flamholc L; Sönnerborg A
PLoS One; 2017; 12(7):e0180140. PubMed ID: 28727795
[TBL] [Abstract][Full Text] [Related]
2. Determinants of switch to paediatric second-line antiretroviral therapy after first-line failure in Cameroon.
Njom-Nlend AE; Efouba N; Brunelle Sandie A; Fokam J
Trop Med Int Health; 2021 Aug; 26(8):927-935. PubMed ID: 33905593
[TBL] [Abstract][Full Text] [Related]
3. Virological failure and treatment switch after ART initiation among people living with HIV with and without routine viral load monitoring in Asia.
Teeraananchai S; Law M; Boettiger D; Mata N; Gupte N; Chan YL; Pham TN; Chaiwarith R; Ly PS; Chan YJ; Kiertiburanakul S; Khusuwan S; Zhang F; Yunihastuti E; Kumarasamy N; Pujari S; Azwa I; Somia IKA; Tanuma J; Ditangco R; Choi JY; Ng OT; Do CD; Gani Y; Ross J; Jiamsakul A;
J Int AIDS Soc; 2022 Aug; 25(8):e25989. PubMed ID: 36028921
[TBL] [Abstract][Full Text] [Related]
4. A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria.
Gilks CF; Walker AS; Munderi P; Kityo C; Reid A; Katabira E; Goodall RL; Grosskurth H; Mugyenyi P; Hakim J; Gibb DM;
PLoS One; 2013; 8(2):e57580. PubMed ID: 23437399
[TBL] [Abstract][Full Text] [Related]
5. Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda.
Ssempijja V; Nakigozi G; Chang L; Gray R; Wawer M; Ndyanabo A; Kasule J; Serwadda D; Castelnuovo B; Hoog AV; Reynolds SJ
BMC Infect Dis; 2017 Aug; 17(1):582. PubMed ID: 28830382
[TBL] [Abstract][Full Text] [Related]
6. Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch.
Johnston V; Cohen K; Wiesner L; Morris L; Ledwaba J; Fielding KL; Charalambous S; Churchyard G; Phillips A; Grant AD
J Infect Dis; 2014 Mar; 209(5):711-20. PubMed ID: 23943851
[TBL] [Abstract][Full Text] [Related]
7. Short Communication: Impact of Viral Load Use on Treatment Switch in Perinatally HIV-Infected Children in Asia.
Jamal Mohamed T; Teeraananchai S; Kerr S; Phongsamart W; Nik Yusoff NK; Hansudewechakul R; Ly PS; Nguyen LV; Sudjaritruk T; Lumbiganon P; Do VC; Kurniati N; Kumarasamy N; Wati DK; Fong MS; Nallusamy R; Kariminia A; Sohn AH
AIDS Res Hum Retroviruses; 2017 Mar; 33(3):230-233. PubMed ID: 27758114
[TBL] [Abstract][Full Text] [Related]
8. Virologic response of treatment experienced HIV-infected Ugandan children and adolescents on NNRTI based first-line regimen, previously monitored without viral load.
Kibalama Ssemambo P; Nalubega-Mboowa MG; Owora A; Serunjogi R; Kironde S; Nakabuye S; Ssozi F; Nannyonga M; Musoke P; Barlow-Mosha L
BMC Pediatr; 2021 Mar; 21(1):139. PubMed ID: 33752636
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.
Boender TS; Hoenderboom BM; Sigaloff KC; Hamers RL; Wellington M; Shamu T; Siwale M; Labib Maksimos EE; Nankya I; Kityo CM; Adeyemo TA; Akanmu AS; Mandaliya K; Botes ME; Ondoa P; Rinke de Wit TF
Clin Infect Dis; 2015 Dec; 61(11):1749-58. PubMed ID: 26240203
[TBL] [Abstract][Full Text] [Related]
10. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
[TBL] [Abstract][Full Text] [Related]
11. Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial.
Szubert AJ; Prendergast AJ; Spyer MJ; Musiime V; Musoke P; Bwakura-Dangarembizi M; Nahirya-Ntege P; Thomason MJ; Ndashimye E; Nkanya I; Senfuma O; Mudenge B; Klein N; Gibb DM; Walker AS;
PLoS Med; 2017 Nov; 14(11):e1002432. PubMed ID: 29136032
[TBL] [Abstract][Full Text] [Related]
12. Time to Switch to Second-line Antiretroviral Therapy in Children With Human Immunodeficiency Virus in Europe and Thailand.
European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord
Clin Infect Dis; 2018 Feb; 66(4):594-603. PubMed ID: 29029056
[TBL] [Abstract][Full Text] [Related]
13. Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa.
Rohr JK; Ive P; Horsburgh CR; Berhanu R; Shearer K; Maskew M; Long L; Sanne I; Bassett J; Ebrahim O; Fox MP
PLoS One; 2016; 11(8):e0161469. PubMed ID: 27548695
[TBL] [Abstract][Full Text] [Related]
14. Outcomes after viral load rebound on first-line antiretroviraltreatment in children with HIV in the UK and Ireland: an observational cohort study.
Childs T; Shingadia D; Goodall R; Doerholt K; Lyall H; Duong T; Judd A; Gibb DM; Collins IJ;
Lancet HIV; 2015 Apr; 2(4):e151-8. PubMed ID: 26413561
[TBL] [Abstract][Full Text] [Related]
15. Switching to second-line ART in relation to mortality in a large Tanzanian HIV cohort.
Hawkins C; Hertzmark E; Spiegelman D; Muya A; Ulenga N; Kim S; Khudyakov P; Christian B; Sando D; Aris E; Fawzi W
J Antimicrob Chemother; 2017 Jul; 72(7):2060-2068. PubMed ID: 28387836
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.
Penazzato M; Prendergast A; Tierney J; Cotton M; Gibb D
Cochrane Database Syst Rev; 2012 Jul; (7):CD004772. PubMed ID: 22786492
[TBL] [Abstract][Full Text] [Related]
17. Predictors of treatment failure and time to detection and switching in HIV-infected Ethiopian children receiving first line anti-retroviral therapy.
Bacha T; Tilahun B; Worku A
BMC Infect Dis; 2012 Aug; 12():197. PubMed ID: 22916836
[TBL] [Abstract][Full Text] [Related]
18. Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.
Penazzato M; Prendergast AJ; Muhe LM; Tindyebwa D; Abrams E
Cochrane Database Syst Rev; 2014 May; 2014(5):CD004772. PubMed ID: 24852077
[TBL] [Abstract][Full Text] [Related]
19. High rate of virological failure and low rate of switching to second-line treatment among adolescents and adults living with HIV on first-line ART in Myanmar, 2005-2015.
Kyaw NT; Harries AD; Kumar AM; Oo MM; Kyaw KW; Win T; Aung TK; Min AC; Oo HN
PLoS One; 2017; 12(2):e0171780. PubMed ID: 28182786
[TBL] [Abstract][Full Text] [Related]
20. Treatment failure and drug resistance in HIV-positive patients on tenofovir-based first-line antiretroviral therapy in western Kenya.
Brooks K; Diero L; DeLong A; Balamane M; Reitsma M; Kemboi E; Orido M; Emonyi W; Coetzer M; Hogan J; Kantor R
J Int AIDS Soc; 2016; 19(1):20798. PubMed ID: 27231099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
